News & Press Releases
Sparrow Pharmaceuticals to Present Two Abstracts at ACR Convergence 2024 and Expand Phase 2 Clinical Trial of Clofutriben with Prednisolone for Polymyalgia Rheumatica to Fifth Cohort
Sparrow Pharmaceuticals will present interim data from the ongoing Phase 2 trial of lead agent clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the American College of Rheumatology Convergence 2024 conference. Sparrow also announced that the trial has been expanded with a fifth cohort based on encouraging results from the first four cohorts.
Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA Orphan Drug Designation of Clofutriben for Endogenous Cushing’s Syndrome
Sparrow Pharmaceuticals announced that the Phase 2 RESCUE trial of clofutriben for the treatment of endogenous Cushing’s syndrome is complete. Clofutriben has also been granted Orphan Drug Designation by the FDA for the treatment of endogenous Cushing’s syndrome.
Sparrow Pharmaceuticals Presented New Data on Clofutriben and Prednisolone for Polymyalgia Rheumatica Treatment at DGRh Kongress 2024
Sparrow Pharmaceuticals today announced that it presented new data of its HSD-1 inhibitor, clofutriben in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) at the German Congress of Rheumatology (DGRh Kongress 2024) in Dusseldorf, Germany.
Sparrow Pharmaceuticals Presents Data from Ongoing Phase 2 Trial of Clofutriben (SPI-62) and Prednisolone as a Treatment for Polymyalgia Rheumatica at EULAR 2024
Sparrow Pharmaceuticals today presented data from an ongoing Phase 2 clinical trial that suggest HSD-1 inhibition can allow for effective treatment with glucocorticoid medicines with fewer side effects.
Sparrow Pharmaceuticals Presents Novel Data on Clofutriben (SPI-62) Reducing Glucocorticoid Toxicities with a Low Risk of Adrenal Insufficiency at the 2024 Annual Endocrine Society Conference
Sparrow Pharmaceuticals announced today that, to date, the HSD-1 inhibitor clofutriben (SPI-62) has normalized urine free cortisol (UFC) in >60% of patients with endogenous Cushing’s syndrome (EnCS) without suppressing serum cortisol to levels considered to indicate risk for adrenal insufficiency (AI).
Sparrow Pharmaceuticals’ David Katz, PhD, to Receive Outstanding Innovation Award at the 2024 Annual Endocrine Society Conference
Sparrow Pharmaceuticals’ David Katz, PhD, to Receive Outstanding Innovation Award at the 2024 Annual Endocrine Society Conference
Sparrow Pharmaceuticals Expands PROST! with Fourth Cohort in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
Sparrow Pharmaceuticals has continued to expand its PROST! Phase 2 clinical trial (NCT05436652) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) with a fourth cohort.
Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion
Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of autonomous cortisol secretion (ACS).
Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
Sparrow Pharmaceuticals today announced the expansion of its PROST! Phase 2 clinical trial of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
Sparrow Pharmaceuticals Announces First Patient Rolled-Over to Open-Label Extension of RESCUE, a Phase 2 Clinical Trial of SPI-62 for ACTH-Dependent Cushing’s Syndrome
Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.
Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference
Sparrow Pharmaceuticals will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference.
Sparrow Pharmaceuticals Presents ePoster on SPI-62 at the 25th European Congress of Endocrinology
Sparrow Pharmaceuticals presented an ePoster on SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).
Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort
Sparrow Pharmaceuticals has expanded its Phase 2 clinical trial of prednisolone in combination with SPI-62 for the treatment of polymyalgia rheumatica (PMR) with the introduction of a second cohort to the study.
Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022
Sparrow Pharmaceuticals today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting. The presentation titled, “Toward Safer Glucocorticoid Therapy” examined the ability of SPI-62 to mitigate the adverse effects of exogenously administered corticosterone (CORT) in mouse, with results suggesting SPI-62 has the potential to prevent the adverse effects of glucocorticoids.
Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE, a Phase 2 Clinical Trial of SPI-62 for Cushing’s Syndrome
Sparrow Pharmaceuticals today announced that the first patient has been dosed in the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome.
Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
Sparrow Pharmaceuticals today announced that the first patient has been dosed in a phase 2 clinical trial of prednisolone in combination with SPI-62, Sparrow’s potent and selective investigational HSD-1 inhibitor, for the treatment of polymyalgia rheumatica (PMR), a common autoimmune disease that causes widespread muscle pain and stiffness primarily in adults over 50. A fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.
Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting
Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).
Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology
Sparrow Pharmaceuticals today presented new animal model data during an in-person poster session titled, “Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica” at the 2022 Annual European Congress of Rheumatology (EULAR 2022). The results of the study suggest that SPI-62 has the potential to mitigate adverse effects of glucocorticoids.
Sparrow Pharmaceuticals Presents New Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the 24th European Congress of Endocrinology
Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).
Sparrow Pharmaceuticals Announces FDA Clearance of IND for SPI-62 for the Treatment of Cushing’s Syndrome
Sparrow Pharmaceuticals today announced that the FDA has cleared an IND that enables the company to proceed with initiating a phase 2 clinical trial to study SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The company also announced that it has expanded its clinical capabilities by hiring Kim Hunsicker as Head of Clinical Operations and Sarah Hooper as Clinical Project Manager.